Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345, an mRNA Vaccine Against RSV, Administered 12 Months Following a Primary Dose in Adults Aged ≥50 Years
- Journal:
- Clinical Infectious Diseases
- Published:
- DOI:
- 10.1093/cid/ciaf515
- Affiliations:
- 3
- Authors:
- 19
| Institutions | Authors | Share |
|---|---|---|
| Moderna, United States of America (USA) | 0.89 | |
| Indago Research, United States of America (USA) | 0.05 | |
| Suncoast Research Associates, LLC, United States of America (USA) | 0.05 |